Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis

REFERENCES

• Moffett JR, Namboodiri MA, Cangro CB, et al. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2: 131–134
   PubMed Web of Science ®Google Scholar
• Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37–45
   PubMed Web of Science ®Google Scholar
• Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15 (4 Suppl.): 46S-57S
   Google Scholar
• Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease. Magn Reson Med 1990; 14: 154–159
   PubMed Web of Science ®Google Scholar
• Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005; 65: 1626–1630
   PubMed Web of Science ®Google Scholar
• Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantita-tive proton MR spectroscopy. AJNR Am] Neuroradiol 1999; 20: 1619-1927
   Google Scholar
• Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248: 979–986
   PubMed Web of Science ®Google Scholar
• Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myel inated axons. J Neurosci 1998; 18: 1953–1962
   PubMed Web of Science ®Google Scholar
• Dautry C, Vaufrey F, Brouillet E, et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-n itropropionic acid. J Cereb Blood Flow Metab 2000; 20: 789–799
   PubMed Web of Science ®Google Scholar
• Arnold DL, Wolinsky JS, Matthews PM, et al. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64 (Suppl. 1): S94—S101
   Google Scholar
• Arnold DL, Matthews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31: 235–241
   PubMed Web of Science ®Google Scholar
• Clanet M, Berry I. Magnetic resonance imaging in multiple sclerosis. Curr Opin Neurol 1998; 11: 299–303
   PubMed Web of Science ®Google Scholar
• Adams CW, Poston RN, Buk Si. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92: 291–306
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, Fenstermacher Mi. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40: 1764-1769
   Google Scholar
• Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectro-scopy at 3 T. Brain 2005; 128: 1016–1025
   PubMed Web of Science ®Google Scholar
• Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002; 8: 207–210
   PubMed Web of Science ®Google Scholar
• Vrenken H, Barkhof F, Uitdehaag BM, et al.MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005; 53: 256–266
   PubMed Web of Science ®Google Scholar
• Narayana PA, Doyle Ti, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56–71
   PubMed Web of Science ®Google Scholar
• Mader I, Seeger U, Weissert R, et al. Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. Brain 2001; 124: 953–961
   PubMed Web of Science ®Google Scholar
• Simone IL, Tortorella C, Federico F, et al. Axonal damage in multiple sclerosis plaques: A combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study. J Neurol Sci 2001; 182: 143–150
   PubMed Web of Science ®Google Scholar
• He J, Inglese M, Li BS, et a/Relapsing-remitting multiple sclerosis: Metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: Initial experience. Radiology 2005; 234: 211–217
   PubMed Web of Science ®Google Scholar
• Inglese M, Grossman RI, Filippi M. Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution. J Neuroimaging 2005; 15 (4 Suppl.): 22S-29S
   Google Scholar
• Staffen W, Zauner H, Mair A, et al. Magnetic resonance spectro-scopy of memory and frontal brain region in early multiple sclerosis. J Neuropsychiatry Clin Neurosci 2005; 17: 357–363
   PubMed Web of Science ®Google Scholar
• Siger-Zajdel M, Selmaj KW. Proton magnetic resonance spectro-scopy of normal appearing white matter in familial and sporadic multiple sclerosis. J Neurol 2005; 252: 830–832
   PubMed Web of Science ®Google Scholar
• Inglese M, Li BS, Rusinek H, et al.Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003; 50: 190–195
   PubMed Web of Science ®Google Scholar
• Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: Proton magnetic resonance spectroscopic imaging. Mult Scler 2001; 7: 221–226
   PubMed Web of Science ®Google Scholar
• Inglese M, Liu S, Babb JS, et al. Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS. Neurology 2004; 63: 170–172
   PubMed Web of Science ®Google Scholar
• Schubert F, Seifert F, Elster C, et al.Serial 1H-MRS in relapsing-remitting multiple sclerosis: Effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA 2002; 14: 213–222
   PubMedGoogle Scholar
• Sarchielli P, Presciutti 0, Tarducci R, et al.1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-la: Results of a preliminary study. J Neurol Neurosurg Psychiatry 1998; 64: 204–212
   PubMed Web of Science ®Google Scholar
• Tedeschi G, Gallo A. Multiple sclerosis patients and immunomo-dulation therapies: The potential role of new MRI techniques to assess responders versus non-responders. Neurol Sci 2005; 26 (Suppl. 4): S209—S212
   Google Scholar
• Parry A, Corkill R, Blamire AM, et al. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003; 250: 171–178
   PubMed Web of Science ®Google Scholar